THERAPY DOSSIER · th-9498d2e0194f

Bone-marrow-derived mesenchymal stromal cells pretreated with interferon-gamma

Biologic · Cell therapy (IFN-gamma-primed bone-marrow MSCs); not a ChEMBL entity

Evidence & regulatory context

Mechanism: Cell therapy (IFN-gamma-primed bone-marrow MSCs); not a ChEMBL entity
Target: Not recorded
Injury models: Burn
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05035862 ↗PHASE1terminated

IFN-gamma-primed Mesenchymal Stromal Cells for Moderate-to-severe Persistent Asthma

Asthma

Enrolment: 1 · Results not recorded

NCT04489732 ↗PHASE1completed

IFN-gamma Stimulated Bone-marrow MSCs for Xerostomia After Radiotherapy

Xerostomia

Enrolment: 6 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24849741 ↗2014Reported benefit

Modulation of the early inflammatory microenvironment in the alkali-burned eye by systemically administered interferon-gamma-treated mesenchymal stromal cells.

MouseBurnChemical / corrosiveBALB/cFemaleIntravenous24 h after the injury

Model: Alkali burn of the eye

Labelled cells were more than 30 times more abundant in damaged than control eyes, and only interferon-gamma-pretreated cells significantly reduced the percentage of eye-infiltrating cells, with the largest effect on myeloid cells and significant falls in IL-1 alpha, IL-6 and nitric oxide.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…